Ataraxia VC | Activity | F4

Team Portfolio Raise Essays

F4/Ataraxia VC/Activity

Ataraxia VC Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

ResMed closed its $340M acquisition of Noctrix Health, developer of the FDA-cleared Nidra neuromodulation wearable for restless legs syndrome. Deal announced April 30, 2026 and closed June 1, 2026. Noctrix is an Ataraxia portfolio company.

Noctrix Health

Noctrix Health Ataraxia VC

fiercebiotech.comJUN 1, 2026

JUN 1, 2026

Milestone

Portfolio company Gourmey acquired Vital Meat to form PARIMA, a global leader in cultivated meat production.

Gourmey

GourmeyVital MeatAtaraxia VC

foodnavigator.comOCT 15, 2025

OCT 15, 2025

Investment

Ataraxia participated in Noctrix Health's $33.5M Series C continuation financing for Nidra therapy (FDA-cleared medical device for restless leg syndrome).

Noctrix Health

Noctrix Health Ataraxia VC

f4.fundOCT 2025

OCT 2025

Exit

Portfolio company Orbillion Bio acquired by Fork & Good, consolidating cultivated meat technology platforms.

Orbillion Bio

Orbillion BioAtaraxia VC

forkandgood.comOCT 2025

OCT 2025

Investment

Participated in Noctrix Health's $33.5M Series C continuation financing for Nidra therapy (FDA-cleared medical device for restless leg syndrome).

Noctrix Health

Noctrix Health Ataraxia VC

businesswire.comAUG 2025

AUG 2025

Investment

Participated in Planted's Series B funding round for plant-based protein alternatives.

Planted

Planted Ataraxia VC

plantedfoods.comDEC 2024

DEC 2024